): Graft-versus-host disease (GvHD) remains the most common cause of non-relapse mortality post hematopoietic cell transplant (HCT). Up to 40% of HCT recipients will fail first-line immunoprophylaxis and ultimately develop GvHD. Standard-of-care strategies for GvHD have not changed in decades and new therapies are desperately needed. Our team is currently enrolling patients in a Phase II clinical trial of Abatacept, a T cell costimulatory inhibitor as an adjunct to standard GvHD immunoprophylaxis, which is currently supported by an R01 mechanism under the Clinical Studies of Safety and Effectiveness of Orphan Products Program. In this Competing Supplement application, we propose to perform a critical correlative biology study that is expected to provide insights into the mechanisms that drive breakthrough GVHD. In the proposed study, we will perform a retrospective, case-matched, correlative biology study with samples from the Abatacept Phase II (ABA-02) clinical trial biorepository. Using next-generation sequencing technology, we will identify the mechanism of breakthrough GvHD in patients being treated on the ABA-02 study. We will also sequence patient samples prior to the onset of clinical GvHD, in order to identify gene signatures associated with sub-clinical GvHD. These studies will provide mechanistic insights into the factors that control breakthrough GvHD, and lay the foundation for a risk-stratified approach to GvHD prevention.

Public Health Relevance

Our proposed research will positively impact public health by identifying the mechanisms of treatment failure for hematopoietic cell transplant recipients who ultimately fail prophylactic therapy for graft-versus-host disease. The determination of these causative mechanisms will improve the transplant outcomes, and therefore, the lives of patients undergoing hematopoietic stem cell transplantation.

Agency
National Institute of Health (NIH)
Institute
Food and Drug Administration (FDA)
Type
Research Project (R01)
Project #
3R01FD004099-04S1A1
Application #
9212551
Study Section
Special Emphasis Panel (ZFD1-SRC (99))
Project Start
2013-05-01
Project End
2017-07-31
Budget Start
2016-08-01
Budget End
2017-07-31
Support Year
4
Fiscal Year
2016
Total Cost
$99,630
Indirect Cost
Name
Seattle Children's Hospital
Department
Type
DUNS #
048682157
City
Seattle
State
WA
Country
United States
Zip Code
98101
Rogatko, André; Cook-Wiens, Galen; Tighiouart, Mourad et al. (2015) Escalation with Overdose Control is More Efficient and Safer than Accelerated Titration for Dose Finding. Entropy (Basel) 17:5288-5303
Suessmuth, Yvonne; Mukherjee, Rithun; Watkins, Benjamin et al. (2015) CMV reactivation drives posttransplant T-cell reconstitution and results in defects in the underlying TCR? repertoire. Blood 125:3835-50